Seeking Alpha

Micromet (MITI) says it entered into a collaboration agreement with Amgen (AMGN) for the...

Micromet (MITI) says it entered into a collaboration agreement with Amgen (AMGN) for the research of BiTE antibodies designed to direct the body's cell-destroying T-cells against tumor cells, representing a new therapeutic approach to cancer therapy. MITI +4.5%, AMGN -0.8% premarket. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs